Literature DB >> 31213358

Diffuse Primary Cutaneous Anaplastic Large Cell Lymphoma Treated by Rotational Total Skin Electron Beam Radiotherapy with Custom Shielding: Case Report.

Alexander D Sherry1, George X Ding2, Austin N Kirschner3.   

Abstract

INTRODUCTION: Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare T-cell malignancy typically presenting as a solitary lesion treated with radiotherapy. Diffuse PCALCL is rare, and treatment paradigms of diffuse PCALCL are poorly defined. CASE AND OUTCOMES: In this report, a 69-year-old male presented with progressive extensive truncal PCALCL resistant to brentuximab. The truncal lesions were treated with 36 Gy in 18 fractions by a novel approach using rotational electron beam radiation therapy with custom-made shielding. The treatment was well tolerated with expected dermatologic side effects managed supportively. All lesions achieved an initial complete response, and two sites within the treatment field recurred five months after treatment. DISCUSSION: This case adds to the limited literature on diffuse PCALCL and demonstrates an uncommon treatment approach to multifocal PCALCL using rotational electron beam radiation therapy with personalized shielding techniques. The treatment approach here was well tolerated by the patient with initial complete response at all sites. Maximal sparing was especially critical in this patient because of a history of previous head and neck irradiation. Shielded areas were validated by optically stimulated luminescent dosimeters showing dose reduction, confirming the utility of this method.
CONCLUSION: Rotational total skin electron beam with personalized shielding may be generalizable to cutaneous malignancies including PCALCL presenting with diffuse skin involvement. Further investigation of diffuse PCALCL is merited to optimize treatment strategies.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Electron shielding; T-lymphocytes; cutaneous radiotherapy; lymphoma; rotational electron beam radiotherapy

Mesh:

Year:  2019        PMID: 31213358      PMCID: PMC6746599          DOI: 10.1016/j.jmir.2019.05.002

Source DB:  PubMed          Journal:  J Med Imaging Radiat Sci        ISSN: 1876-7982


  23 in total

Review 1.  Primary cutaneous anaplastic large-cell lymphoma.

Authors:  Edward Perry; Jay Karajgikar; Imad A Tabbara
Journal:  Am J Clin Oncol       Date:  2013-10       Impact factor: 2.339

2.  Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.

Authors:  M W Bekkenk; F A Geelen; P C van Voorst Vader; F Heule; M L Geerts; W A van Vloten; C J Meijer; R Willemze
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

Review 3.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

Review 4.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

5.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors:  Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2008-04-02       Impact factor: 22.113

6.  Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database.

Authors:  James B Yu; Rachel C Blitzblau; Roy H Decker; Douglas M Housman; Lynn D Wilson
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

7.  CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.

Authors:  Howard L Liu; Richard T Hoppe; Sabine Kohler; Jeff D Harvell; Sunil Reddy; Youn H Kim
Journal:  J Am Acad Dermatol       Date:  2003-12       Impact factor: 11.527

8.  FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma.

Authors:  Phillip H Kuo; Bruce L McClennan; Kacie Carlson; Lynn D Wilson; Richard L Edelson; Peter W Heald; Michael Girardi
Journal:  Mol Imaging Biol       Date:  2008-01-15       Impact factor: 3.488

Review 9.  Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.

Authors:  Marshall E Kadin
Journal:  Oncology (Williston Park)       Date:  2009-11-30       Impact factor: 2.990

10.  Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.

Authors:  Denise K Woo; Christopher R Jones; Monique N Vanoli-Storz; Sabine Kohler; Sunil Reddy; Ranjana Advani; Richard T Hoppe; Youn H Kim
Journal:  Arch Dermatol       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.